United States

Developed Europe

Developed Rest of World

Emerging Markets

Total Internetional

Revenue by Geography

Revenue segments as reported by the company.

Primary Care

Specialty Care

Oncology

Pfizer CentreOne

Vaccines

Hospital

Internal Medicine

Rare Disease

Inflammation & Immunology

Pfizer Ignite

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions

Acquired in-process research and development expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pfizer

Sildenafil is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is sold as the brand name Viagra among others.

Viagra

Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. It is marketed under the trade name Lipitor among others

Lipitor

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pfizer exceeds $100B in revenue, eyes growth amid challenges

Pfizer's exceptional 2022 performance sets the stage for continued success in 2023.
Strategic investments in R&D and new product launches drive revenue growth expectations.
Challenges include transitioning from emergency status and revenue decline from COVID-related products.
Opportunities lie in increased adoption of combo vaccines and business development goals.

Pfizer reports solid Q1 results, eyes growth through innovation

Pfizer's Q1 performance was strong, driven by revenue growth and patient reach.
The company faces challenges in COVID franchise transition and stock performance.
Strategic acquisitions, new product launches, and market monitoring offer growth opportunities.
Pfizer's focus on innovation, trustworthiness, and commercial efficiency underpin its future success.

Pfizer reports Q2 growth amidst COVID uncertainties and therapeutic optimism

Pfizer's Q2 performance reflects growth in non-COVID revenues, strategic acquisitions, and a focus on new product launches. Challenges include uncertainties in revenue forecasts and operational adjustments post-acquisitions. Opportunities lie in therapeutic advancements and the potential of mRNA flu vaccines.

Pfizer reports strong Q3 performance, eyes growth in non-COVID products

Pfizer's Q3 performance showcased resilience in non-COVID product revenue growth, offsetting COVID-related declines. The company's strategic focus on global health impact and innovative acquisitions positions it for future growth. Challenges in the COVID product segment persist, but Pfizer remains optimistic about opportunities in new product launches and cancer treatment advancements.

Pfizer reports solid 2023 performance, eyes growth and cost savings

Pfizer's 2023 performance was strong despite challenges, with a focus on oncology, R&D, and cost savings. The company aims for revenue growth in 2024, emphasizing shareholder value and strategic priorities.

Pfizer reports robust Q1 earnings, eyes international growth and pipeline

Pfizer's Q1 2024 performance showcased strong revenue figures and strategic focus on non-COVID products and oncology, underlining the company's resilience and growth potential.
While facing challenges in adult market contraction and gross margin issues, Pfizer's strengths in pipeline innovation, product performance, and international market growth position it well for the future.
The company's opportunities lie in continued international expansion, consumer engagement initiatives, and upcoming pipeline advancements, signaling a path for sustained growth and innovation.

Pfizer reports strong Q2 earnings, raises guidance amid leadership changes

Pfizer's Q2 2024 earnings call reflects a robust performance, marked by revenue growth, leadership changes, and enhanced guidance. The company's strategic focus on oncology, vaccines, and product differentiation positions it for continued success. Challenges include maintaining market share post-generics and managing growth expectations for VYNDAQEL.

Pfizer reports robust Q3 earnings, eyes international market growth

Pfizer's Q3 earnings call highlighted strong performance, pipeline advancements, and a focus on shareholder value creation. Challenges include addressing the impact of IRA and maintaining growth in specific product lines. Opportunities lie in international market expansion and continued pipeline innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Pfizer Inc. (NYSE: PFE) says it is in the process of working with a third party to screen compounds that may curb coronaviruses.

Pfizer Works On Compounds That May Help Stop Coronaviruses

Johnson & Johnson

Sanofi

Representatives from Sanofi, Pfizer, and Johnson & Johnson are expected to attend the White House session Monday afternoon.

Trump to Meet With Pharmaceutical Companies About Coronavirus

Chevron

Verizon

Verizon Communications Inc 5.9 % Notes 2014-15.2.54 Sr

Exxon Mobil

The six “Dogs of the Dow” for 2020 had an aggregate year-to-date decline of 11.8% in February versus a loss of 11% for the overall Dow Jones Industrial average. What's next?

The ‘Dogs Of The Dow’ Did As Badly As The DJIA In February. Here’s How To Trade Them Now.

Pfizer (PFE) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Is Pfizer (PFE) Stock a Solid Choice Right Now?

Pfizer Inc  on Thursday warned that the continued spread of the coronavirus globally could have an adverse impact on its financial results.

Pfizer warns of hit to financial results on continued coronavirus outbreak

Pfizer (PFE) reported earnings 30 days ago. What's next for the stock?

Why Is Pfizer (PFE) Down 7.6% Since Last Earnings Report?

Apple

Intel

Microsoft

It takes a certain kind of courage to short sell blue chips, such as the Dow Jones industrial average components.

The '5 Most Shorted' Dow Stocks

Mylan

Teva Pharmaceutical

The global reliance on China for APIs and drug manufacturing might hit supply chains and production amid the Coronavirus outbreak. Thus, companies independent of China's input are up for grabs now.

3 Best Drugmakers That Are Immune to Coronavirus Fright

Allegion

SYNNEX

I’m going to show you how to grab two growing income streams—in just one buy.

How To Play Stock Splits For 3X Dividends, 200%+ Upside

Bristol-Myers

GlaxoSmithKline

Novartis

Approvals were down slightly year over year.

FDA Approved 1,014 Generic Drugs in 2019

Pfizer's (PFE) Vyndaqel gets approval in Europe and becomes the first therapy approved to treat ATTR-CM in the continent.

Pfizer's Cardiomyopathy Drug Vyndaqel Gets Approval in Europe

Sales of the treatment got off to a good start in the U.S., and Europe could follow suit.

Pfizer Gains European Approval for Amyloidosis Drug Vyndaqel

Pfizer Inc.-backed biopharma company Imara Inc. filed initial public offering documents late Friday with the Securities and Exchange Commission, planning to list on the Nasdaq Global Market under the ticker symbol "IMRA.

Pfizer-backed biopharma company Imara files for IPO

Pfizer's (PFE) Xtandi demonstrates a significant improvement in overall survival in the late-stage PROSPER study that evaluated the drug in men with non-metastatic castration-resistant prostate cancer.

Pfizer's Xtandi Improves OS Rate in Prostate Cancer Study

The '5 Most Shorted'  Dow Stocks

Pfizer stock tumbled below other pharma stocks on key metrics in 2019. Recent news has been upbeat with a drug approval and acquisitions.

Pfizer Stock Tumbled On Its Earnings Report — Should You Add Shares?

AbbVie

Which of these highly coveted dividend stocks is the choice right now?

Better Buy: Pfizer vs. AbbVie

Pfizer is down 10% over the past 12 months, although it has shown signs of life as of late.

Should Investors Buy Pfizer on the Dip?

AstraZeneca

Raymond James

Analysts at investment bank Raymond James theorize that the trend will continue.

Analysis: Major Pharmaceuticals' January Drug Price Hikes Were Smallest in at Least 6 Years

Mylan Looks Attractive Heading Into Merger With Pfizer's Upjohn

Coca-Cola

Check out these three dividend-paying stocks that investors might want to buy to help combat coronavirus-based market pullback fears.

3 Dividend-Paying Stocks for Investors to Buy to Fight Off Market Uncertainty

Amazon

Procter & Gamble

Q4 Earnings Scorecard and Analyst Reports for Amazon, Pfizer & Others

Assuming the European Commission follows the recommendation of its scientific committee, this will be the fifth oncology biosimilar from Pfizer approved in Europe.

Pfizer's Biosimilar Ruxience Gets EU Regulatory Backing

Despite a poorly received fourth-quarter earnings report, Pfizer's the industry's best dividend-paying stock.

5 Reasons Pfizer Is Big Pharma's Top Dividend Stock to Buy Right Now

Pfizer Misses Target, Soft Guidance, And Other News: The Good, Bad And Ugly Of Biopharma

News for Pfizer Stock (PFE)